<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03023241</url>
  </required_header>
  <id_info>
    <org_study_id>9900.013 BPS/IC study</org_study_id>
    <secondary_id>KEKTGOV2010/01</secondary_id>
    <nct_id>NCT03023241</nct_id>
  </id_info>
  <brief_title>Diagnosis of Bladder Pain Syndrome / Interstitial Cystitis</brief_title>
  <official_title>Diagnosis of Bladder Pain Syndrome / Interstitial Cystitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cantonal Hospital, Frauenfeld</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cantonal Hospital, Frauenfeld</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To identify new, simple and reliable biomarkers for bladder pain syndrome/interstitial
      cystitis (BPS/IC) for diagnosis of this disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Collection and analyses of bladder biopsies, bladder washings, blood and urine samples of
      patients with bladder pain syndrome/interstitial cystitis (BPS/IC), overactive bladder
      syndrome (OAB) and bladder-healthy controls. Analyses include ELISA, RT-qPCR, DNA sequencing,
      and immunohistochemistry techniques. Differences between patient groups are statistically
      evaluated.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2004</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Identification of new diagnostic markers for BPS/IC</measure>
    <time_frame>2 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Identification of molecular details that lead to BPS/IC (pathogenesis).</measure>
    <time_frame>2 days</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Bladder Pain Syndrome</condition>
  <condition>Interstitial Cystitis</condition>
  <condition>Overactive Bladder</condition>
  <arm_group>
    <arm_group_label>all study patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Same intervention for all subjects: anamnesis, questionnaires and biological samples (bladder biopsy, bladder washing, blood and urine) are collected at one single visit.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>biopsy</intervention_name>
    <description>cold cup bladder biopsies and bladder washings under anesthesia, blood and urine collection</description>
    <arm_group_label>all study patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patient with diagnosed BPS/IC, OAB or healthy controls

          -  included healthy controls must have another pelvic surgery planned (e.g. hysterectomy)

          -  being able to act and judge

        Exclusion Criteria:

          -  unstable endocrinological situation

          -  severe illness
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Volker Viereck, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cantonal Hospital Frauenfeld, Switzerland</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marianne Gamper, Dr.</last_name>
    <phone>+41 52 723 81 69</phone>
    <email>marianne.gamper@stgag.ch</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cantonal Hospital Frauenfeld</name>
      <address>
        <city>Frauenfeld</city>
        <state>Thurgau</state>
        <zip>8501</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Volker Viereck, MD</last_name>
      <email>volker.viereck@stgag.ch</email>
    </contact>
    <contact_backup>
      <last_name>Marianne Gamper, PhD</last_name>
      <email>marianne.gamper@stgag.ch</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <results_reference>
    <citation>Gamper M, Viereck V, Geissb√ºhler V, Eberhard J, Binder J, Moll C, Rehrauer H, Moser R. Gene expression profile of bladder tissue of patients with ulcerative interstitial cystitis. BMC Genomics. 2009 Apr 28;10:199. doi: 10.1186/1471-2164-10-199.</citation>
    <PMID>19400928</PMID>
  </results_reference>
  <results_reference>
    <citation>Gamper M, Viereck V, Eberhard J, Binder J, Moll C, Welter J, Moser R. Local immune response in bladder pain syndrome/interstitial cystitis ESSIC type 3C. Int Urogynecol J. 2013 Dec;24(12):2049-57. doi: 10.1007/s00192-013-2112-0. Epub 2013 May 14.</citation>
    <PMID>23670165</PMID>
  </results_reference>
  <results_reference>
    <citation>Gamper M, Regauer S, Welter J, Eberhard J, Viereck V. Are mast cells still good biomarkers for bladder pain syndrome/interstitial cystitis? J Urol. 2015 Jun;193(6):1994-2000. doi: 10.1016/j.juro.2015.01.036. Epub 2015 Jan 14.</citation>
    <PMID>25596361</PMID>
  </results_reference>
  <results_reference>
    <citation>Gamper M, Moser R, Viereck V. Have we been led astray by the NGF biomarker data? Neurourol Urodyn. 2017 Jan;36(1):203-204. doi: 10.1002/nau.22882. Epub 2015 Sep 18.</citation>
    <PMID>26384156</PMID>
  </results_reference>
  <results_reference>
    <citation>Regauer S, Gamper M, Fehr MK, Viereck V. Sensory Hyperinnervation Distinguishes Bladder Pain Syndrome/Interstitial Cystitis from Overactive Bladder Syndrome. J Urol. 2017 Jan;197(1):159-166. doi: 10.1016/j.juro.2016.06.089. Epub 2016 Jul 1.</citation>
    <PMID>27378135</PMID>
  </results_reference>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 13, 2017</study_first_submitted>
  <study_first_submitted_qc>January 13, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 18, 2017</study_first_posted>
  <last_update_submitted>February 6, 2018</last_update_submitted>
  <last_update_submitted_qc>February 6, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 7, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cantonal Hospital, Frauenfeld</investigator_affiliation>
    <investigator_full_name>Prof. Dr. Volker Viereck</investigator_full_name>
    <investigator_title>Prof. Dr. med.</investigator_title>
  </responsible_party>
  <keyword>BPS/IC</keyword>
  <keyword>OAB</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Urinary Bladder, Overactive</mesh_term>
    <mesh_term>Somatoform Disorders</mesh_term>
    <mesh_term>Cystitis</mesh_term>
    <mesh_term>Cystitis, Interstitial</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

